BENEVOLENTAI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.65 EUR | -4.41% |
|
-1.52% | -39.81% |
| 04-15 | BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024 | CI |
| 04-03 | BenevolentAI Founder Reportedly Calls for Board Revamp | MT |
| Sales 2024 * | 33.62M 42M 39.27M 3.36B | Sales 2025 * | 31.32M 39.13M 36.58M 3.13B | Capitalization | 67.93M 84.86M 79.34M 6.79B |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -7.5M -7.01M -600M | Net income 2025 * | -13M -16.24M -15.18M -1.3B | EV / Sales 2024 * | 1.04 x |
| Net cash position 2024 * | 32.98M 41.2M 38.52M 3.3B | Net cash position 2025 * | 58.24M 72.75M 68.02M 5.82B | EV / Sales 2025 * | 0.31 x |
| P/E ratio 2024 * |
-16.2
x | P/E ratio 2025 * |
-8.93
x | Employees | 248 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.04% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -4.41% | ||
| 1 week | -1.52% | ||
| Current month | -2.99% | ||
| 1 month | -4.41% | ||
| 3 months | -17.72% | ||
| 6 months | -31.58% | ||
| Current year | -39.81% |
1 week
0.65
0.74
1 month
0.620.76
Current year
0.621.41
1 year
0.482.66
3 years
0.4810.00
5 years
0.4810.00
10 years
0.4810.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ivan Griffin
FOU | Founder | 48 | 31/10/13 |
Catherine Isted
DFI | Director of Finance/CFO | - | 10/09/23 |
Francois Nader
CHM | Chairman | 67 | 21/04/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Francois Nader
CHM | Chairman | 67 | 21/04/22 |
| Director/Board Member | 68 | 21/04/22 | |
Nigel Shadbolt
BRD | Director/Board Member | 68 | 30/06/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.65 | -4.41% | 24,533 |
| 25/04/24 | 0.68 | -6.85% | 10,147 |
| 24/04/24 | 0.73 | +7.35% | 17,695 |
| 23/04/24 | 0.68 | +1.49% | 1,310 |
| 22/04/24 | 0.67 | +1.52% | 820 |
Real-time Euronext Amsterdam, April 26, 2024 at 04:35 pm
More quotes
BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.
The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.
Calendar
02/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5571
GBP
Average target price
1.632
GBP
Spread / Average Target
+192.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.81% | 84.62M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BAI Stock
